WO2009055480A3 - Tgf-beta gene expression signature in cancer prognosis - Google Patents

Tgf-beta gene expression signature in cancer prognosis Download PDF

Info

Publication number
WO2009055480A3
WO2009055480A3 PCT/US2008/080802 US2008080802W WO2009055480A3 WO 2009055480 A3 WO2009055480 A3 WO 2009055480A3 US 2008080802 W US2008080802 W US 2008080802W WO 2009055480 A3 WO2009055480 A3 WO 2009055480A3
Authority
WO
WIPO (PCT)
Prior art keywords
tgf
gene expression
expression signature
signature
sample
Prior art date
Application number
PCT/US2008/080802
Other languages
French (fr)
Other versions
WO2009055480A2 (en
Inventor
Snorri S Thorgeirsson
Cedric Coulouarn
Original Assignee
Us Health
Snorri S Thorgeirsson
Cedric Coulouarn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Snorri S Thorgeirsson, Cedric Coulouarn filed Critical Us Health
Publication of WO2009055480A2 publication Critical patent/WO2009055480A2/en
Publication of WO2009055480A3 publication Critical patent/WO2009055480A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention provides methods and kits for determining a prognosis of cancer in a subject by providing a sample taken from a subject, determining a TGF-β signature of the sample using high throughput analysis, and comparing the TGF-β signature of the sample with a control. The aberration of the TGF-β signature of the sample as compared to the control indicates a prognosis of aggressively malignant disease or minimally malignant disease.
PCT/US2008/080802 2007-10-22 2008-10-22 Tgf-beta gene expression signature in cancer prognosis WO2009055480A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98166107P 2007-10-22 2007-10-22
US60/981,661 2007-10-22

Publications (2)

Publication Number Publication Date
WO2009055480A2 WO2009055480A2 (en) 2009-04-30
WO2009055480A3 true WO2009055480A3 (en) 2009-06-11

Family

ID=40512414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/080802 WO2009055480A2 (en) 2007-10-22 2008-10-22 Tgf-beta gene expression signature in cancer prognosis

Country Status (1)

Country Link
WO (1) WO2009055480A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3638695A4 (en) * 2017-06-14 2021-06-30 Icahn School of Medicine at Mount Sinai Methods for the detection and treatment of classes of hepatocellular carcinoma responsive to immunotherapy
WO2020003213A1 (en) * 2018-06-27 2020-01-02 Medpacto, Inc. Methods of diagnosing and treating cancer patients expressing high levels of tgf-b response signature

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040209254A1 (en) * 2000-07-25 2004-10-21 Henderson Lee A. Diagnostic polymorphisms for the tgf-beta1 promoter
US20050009016A1 (en) * 2000-05-04 2005-01-13 Moskowitz David W. Tgfbeta-rII promoter polymorphisms
WO2005024067A2 (en) * 2003-09-04 2005-03-17 Intergenetics, Inc. Genetic analysis for stratification of breast cancer risk
US20060063190A1 (en) * 2004-09-22 2006-03-23 Tripath Imaging, Inc Methods and compositions for evaluating breast cancer prognosis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009016A1 (en) * 2000-05-04 2005-01-13 Moskowitz David W. Tgfbeta-rII promoter polymorphisms
US20040209254A1 (en) * 2000-07-25 2004-10-21 Henderson Lee A. Diagnostic polymorphisms for the tgf-beta1 promoter
WO2005024067A2 (en) * 2003-09-04 2005-03-17 Intergenetics, Inc. Genetic analysis for stratification of breast cancer risk
US20050136438A1 (en) * 2003-09-04 2005-06-23 David Ralph Genetic analysis for stratification of cancer risk
US20060063190A1 (en) * 2004-09-22 2006-03-23 Tripath Imaging, Inc Methods and compositions for evaluating breast cancer prognosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DERYNCK R ET AL: "TGF-beta signaling in tumor suppression and cancer progression.", NATURE GENETICS OCT 2001, vol. 29, no. 2, October 2001 (2001-10-01), pages 117 - 129, XP002523058, ISSN: 1061-4036 *
GARCEA ET AL: "Molecular prognostic markers in pancreatic cancer: A systematic review", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 41, no. 15, 1 October 2005 (2005-10-01), pages 2213 - 2236, XP005104215, ISSN: 0959-8049 *
SIEGEL PETER M ET AL: "Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer.", NATURE REVIEWS. CANCER NOV 2003, vol. 3, no. 11, November 2003 (2003-11-01), pages 807 - 821, XP002523059, ISSN: 1474-175X *

Also Published As

Publication number Publication date
WO2009055480A2 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
WO2008036691A3 (en) Biomarkers for prostate cancer and methods using the same
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2007093657A3 (en) Method for the molecular diagnosis of prostate cancer and kit for implementing same
WO2006135886A3 (en) Compositions and methods for treating and diagnosing cancer
WO2007093050A8 (en) Gene expression assays conducted by elemental analysis
WO2006138275A3 (en) Compositions and methods for treating and diagnosing cancer
WO2010019414A3 (en) Detecting nucleic acid
WO2010083252A3 (en) Ratio based biomarkers and methods of use thereof
WO2007095644A3 (en) Reagents and methods for cancer prognosis and pathological staging
WO2009121032A3 (en) Sample preparation devices and methods for processing analytes
WO2010056351A3 (en) Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and out come prediction in pedeatric b-precursor acute lymphoblastic leukemia
WO2011056866A3 (en) Methods and kits for 3'-end-tagging of rna
WO2006132971A3 (en) Identification of tumors and tissues
WO2012138783A3 (en) Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
WO2009024691A3 (en) Method of assaying leukocyte elastase inhibitor for the in vitro diagnosis of colorectal cancer
WO2009019368A3 (en) Method for the assay of liver fatty acid-binding protein, ace and ca19-9 for the in vitro diagnosis of colorectal cancer
WO2009083950A3 (en) Biomarkers for the prediction of renal injury
WO2009019370A3 (en) Apolipoprotein aii assay method for the in vitro diagnosis of colorectal cancer
WO2009002937A3 (en) Methods for isolating long fragment rna from fixed samples
WO2011112845A3 (en) Methods and compositions related to a multi-methylation assay to predict patient outcome
WO2009020596A3 (en) Embryonic cerebrospinal fluis (e-csf), proteins from e-csf, and related methods and compositions
WO2010034794A3 (en) Methods and kits for the diagnosis and the staging of colorectal cancer
WO2009120183A3 (en) System for the detection of a biological pathogen and use thereof
WO2009058331A3 (en) Biomarkers for the detection of early stage ovarian cancer
WO2009019369A3 (en) I-plastin assay method for the in vitro diagnosis of colorectal cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08843093

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08843093

Country of ref document: EP

Kind code of ref document: A2